Light-chain MGUS: implications for clinical practice.
暂无分享，去创建一个
[1] R. Howard,et al. A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.
[2] R. Hayes,et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.
[3] R. Kyle,et al. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression , 2007, British journal of haematology.
[4] Allan S. Brett,et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .
[5] R. Hoover,et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.
[6] T. Therneau,et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.
[7] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[8] R. Kyle,et al. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. , 1982, The New England journal of medicine.